article thumbnail

Data shows new therapy successfully targets solid tumours

Drug Discovery World

billion by 2026, these drugs are primarily indicated for the treatment of multiple myeloma. AVA3996 is in pre-clinical development with the aim of submitting an Investigational New Drug (IND) application to allow clinical development to begin during 2024.

Therapies 242
article thumbnail

$225m to advance novel immune checkpoint enhancer programme

Drug Discovery World

AltruBio has closed an oversubscribed Series B financing of up to $225 million, which will be used to advance the clinical development of the first-in-class, novel immune checkpoint enhancer (ICE) PSGL-1 agonist antibody, ALTB-268. This study is anticipated to read out in 2H of 2026.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Next steps for the CALYX trial for cerebral Adrenoleukodystrophy 

Drug Discovery World

This will push the Phase III CALYX trial forward and bring leriglitazone to patients as quickly as possible,” said Sílvia Pascual, VP Clinical Development, Minoryx. “In In patients with cALD, appearance of gadolinium-enhancing lesions typically precedes a phase with pronounced lesion growth and rapid clinical deterioration.

Trials 130
article thumbnail

Lessons From A Private Funding Round: Science, Relationships, And Experience

LifeSciVC

We have milestones on the horizon, and we want investors to stay close to the Sionna story even if we don’t need capital until 2026. The insights from these internal discussions refined our messaging and helped demonstrate the compelling opportunity we have to advance a truly groundbreaking clinical development program.

Science 67
article thumbnail

TaiGen Announces FDA Approval of IND for Its Flu Antiviral TG-1000

The Pharma Data

With the IND approval in place, we are ready and eager to extend the clinical study of TG-1000 to the U.S. billion USD by 2026 at a CAGR of 11.5%. Currently the market is comprised primarily of the neuraminidase inhibitor oseltamivir and the newly developed endonuclease inhibitor baloxavir. in the near future.”

article thumbnail

The trends driving ELRIG Drug Discovery 2022

Drug Discovery World

As it stands, there are currently 19 gene therapies approved for clinical use, alongside 18 RNA therapies and 59 non-genetically modified cell therapies, according to the Q2 report by the American Society of Cell & Gene Therapy.

Drugs 130
article thumbnail

Novartis announces new organizational structure

The Pharma Data

“With our portfolio of in-market medicines and up to 20 major pipeline assets that could be approved by 2026, Novartis is in a strong position to deliver above-peer-median sales and margin growth in the mid- and long-term.” ” Integrating Pharmaceuticals and Oncology business units.